112 related articles for article (PubMed ID: 2588144)
1. [Intensive plasmapheresis (programs, laboratory monitoring, complications)].
Malakhovskiĭ IuE; Manerov FK; Makarets BG; Pedanov EA; Romanov MG
Ter Arkh; 1989; 61(7):55-60. PubMed ID: 2588144
[TBL] [Abstract][Full Text] [Related]
2. The impact of different intensities of regular donor plasmapheresis on humoral and cellular immunity, red cell and iron metabolism, and cardiovascular risk markers.
Tran-Mi B; Storch H; Seidel K; Schulzki T; Haubelt H; Anders C; Nagel D; Siegler KE; Vogt A; Seiler D; Hellstern P
Vox Sang; 2004 Apr; 86(3):189-97. PubMed ID: 15078254
[TBL] [Abstract][Full Text] [Related]
3. [The problems of plasma substitution in performing therapeutic plasmapheresis (an evaluation of the efficacy of plasma substitute media and the methods for obtaining them)].
Ryzhko VV; Gorodetskiĭ VM; Aleksanian MZh; Margulis EIa
Ter Arkh; 1989; 61(7):60-5. PubMed ID: 2588145
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic plasmapheresis in immune complex diseases].
Movshev BE; Kalinin NN; Petrova VI
Ter Arkh; 1994; 66(7):70-3. PubMed ID: 7985137
[TBL] [Abstract][Full Text] [Related]
5. [Plasmapheresis in clinical practice].
Malakhovskiĭ IuE; Manerov FK; Gicheva TA; Makarets BG; Romanov MG
Ter Arkh; 1988; 60(5):124-9. PubMed ID: 3175922
[TBL] [Abstract][Full Text] [Related]
6. A prospective multicentre study on the safety of long-term intensive plasmapheresis in donors (SIPLA).
Schulzki T; Seidel K; Storch H; Karges H; Kiessig S; Schneider S; Taborski U; Wolter K; Steppat D; Behm E; Zeisner M; Hellstern P;
Vox Sang; 2006 Aug; 91(2):162-73. PubMed ID: 16907878
[TBL] [Abstract][Full Text] [Related]
7. Reduced blood-to-tissue albumin movement after plasmapheresis.
Stahl AM; Gillen CM; Takamata A; Nadel ER; Mack GW
Shock; 2003 May; 19(5):440-7. PubMed ID: 12744487
[TBL] [Abstract][Full Text] [Related]
8. [Preoperative plasmapheresis].
Schleinzer W; Mehrkens HH; von Bormann B; Weindler M; Wollinsky KH
Klin Wochenschr; 1988; 66 Suppl 15():33-9. PubMed ID: 3184786
[TBL] [Abstract][Full Text] [Related]
9. A prospective trial on the safety of long-term intensive plasmapheresis in donors.
Bechtloff S; Tran-My B; Haubelt H; Stelzer G; Anders C; Hellstern P
Vox Sang; 2005 Apr; 88(3):189-95. PubMed ID: 15787729
[TBL] [Abstract][Full Text] [Related]
10. Prevention of allergic disease in childhood: clinical and epidemiological aspects of primary and secondary allergy prevention.
Halken S
Pediatr Allergy Immunol; 2004 Jun; 15 Suppl 16():4-5, 9-32. PubMed ID: 15125698
[TBL] [Abstract][Full Text] [Related]
11. Complications of double-filtration plasmapheresis.
Yeh JH; Chen WH; Chiu HC
Transfusion; 2004 Nov; 44(11):1621-5. PubMed ID: 15504168
[TBL] [Abstract][Full Text] [Related]
12. [Effect of the method of extracorporeal heparin precipitation of plasma proteins (selective plasmapheresis) on the level of immune complexes in the blood].
Savchenko VG; Margulis EIa; Vasiliev SA; Gorodetskiĭ VM; Ryzhko VV
Ter Arkh; 1985; 57(7):102-7. PubMed ID: 2931844
[TBL] [Abstract][Full Text] [Related]
13. [Plasmapheresis in medical practice].
Łapiński TW; Prokopowicz D
Wiad Lek; 2001; 54(7-8):437-43. PubMed ID: 11641900
[TBL] [Abstract][Full Text] [Related]
14. [Changes in fibronectin concentration during therapeutic plasmapheresis. Therapeutic effectiveness of selective removal of fibronectin in immune complex pathology].
Vasil'ev SA; Savchenko VG; Gorodetskiĭ VM; Ermolin GA; Kotelianskiĭ VE
Ter Arkh; 1984; 56(6):35-9. PubMed ID: 6236575
[TBL] [Abstract][Full Text] [Related]
15. [Osmotic activity of plasma in plasmapheresis in patients with multiple myeloma].
Movshev BE; Kalinin NN; Petrov MM; Petrova VI; Zhuravlev VS; Zakharova ES; Khoroshko ND
Ter Arkh; 2001; 73(2):57-60. PubMed ID: 11338858
[TBL] [Abstract][Full Text] [Related]
16. Hypertonic-hyperoncotic solutions improve cardiac function in children after open-heart surgery.
Schroth M; Plank C; Meissner U; Eberle KP; Weyand M; Cesnjevar R; Dötsch J; Rascher W
Pediatrics; 2006 Jul; 118(1):e76-84. PubMed ID: 16751617
[TBL] [Abstract][Full Text] [Related]
17. [Fractional plasmapheresis in therapeutic experience: methodological approach].
Ibragimov AZ
Klin Med (Mosk); 1997; 75(4):32-4. PubMed ID: 9229629
[TBL] [Abstract][Full Text] [Related]
18. [The treatment potentials of plasmapheresis in glomerulonephritis].
Malakhovskiĭ IuE; Makarets BG; Dantsiger DG; Dobroliubov EE; Korotenko VA; Erikov AL
Ter Arkh; 1991; 63(6):118-22. PubMed ID: 1948726
[TBL] [Abstract][Full Text] [Related]
19. [The monitoring of protein-volemic indices during plasmapheresis in patients with paraproteinemic hemoblastoses].
Kalinin NN; Movshev BE; Petrov MM; Petrova VI; Droshneva VA; Varlamova SV; Khoroshko ND; Zhuravlev VS; Loginov SP
Ter Arkh; 1996; 68(7):62-5. PubMed ID: 8928075
[TBL] [Abstract][Full Text] [Related]
20. [Effect of cryoapheresis on the course of immune complex diseases].
Margulis EIa; Savchenko VG; Zherdeva LV; Tolkachev AA; Selezneva OM
Ter Arkh; 1987; 59(6):80-5. PubMed ID: 2957815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
